Cite
HARVARD Citation
Cella, D. et al. (2022). Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet oncology. 23 (2), pp. 292-303. [Online].